Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.
Read More
Bladder Cancer Journal Vol. 6 Issue 3 The Urinary Microbiome and Bladder Cancer: Susceptibility...
Read More
Bladder Cancer Journal Vol. 6 Issue 2 Considerations about Non-Metastatic Bladder Cancer...
Read More
Bladder Cancer Journal Vol. 6 Issue 1 Chemotherapy Plus Immune Check-Point Inhibitors in...
Read More
Bladder Cancer Journal Vol. 5 Issue 4 Modeling Tumor Heterogeneity in Bladder Cancer: The Current...
Read More